Literature DB >> 9655692

S-adenosylmethionine deficiency and TNF-alpha in lipopolysaccharide-induced hepatic injury.

R K Chawla1, W H Watson, C E Eastin, E Y Lee, J Schmidt, C J McClain.   

Abstract

S-adenosylmethionine (Adomet) is a substrate for de novo synthesis of choline. Adomet deficiency occurs in certain types of liver injury, and the injury is attenuated by exogenous Adomet. Tumor necrosis factor-alpha (TNF-alpha) is also a mediator of these models of hepatotoxicity. We investigated the role of Adomet in lipopolysaccharide (LPS)-induced liver injury in rats made deficient in both Adomet and choline. Rats were maintained on either a methionine-restricted and choline-deficient (MCD) diet or a diet containing sufficient amounts of all nutrients [methionine and choline sufficient (MCS)] and then administered either LPS or saline. MCS-LPS rats had normal liver histology and no change in serum transaminases compared with the MCS-saline control group. MCD-saline rats had hepatosteatosis but no necrosis, and a five- to sevenfold increase in transaminases vs. the MCS-saline group. MCD-LPS rats additionally had hepatonecrosis and a 30- to 50-fold increase in transaminases. Exogenous Adomet administration to MCD-LPS rats corrected the hepatic deficiency of Adomet but not of choline, prevented necrosis but not steatosis, and attenuated transaminases. Serum TNF-alpha was sixfold higher in MCD rats even without LPS challenge and 300-fold higher with LPS challenge. Exogenous Adomet attenuated increased serum TNF-alpha in MCD-LPS rats.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655692     DOI: 10.1152/ajpgi.1998.275.1.G125

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  23 in total

Review 1.  Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.

Authors:  Mazen Noureddin; José M Mato; Shelly C Lu
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-13

2.  Changes in S-adenosylmethionine and GSH homeostasis during endotoxemia in mice.

Authors:  Kwangsuk Ko; Heping Yang; Mazen Noureddin; Ainhoa Iglesia-Ara; Meng Xia; Conrad Wagner; Zigmund Luka; José M Mato; Shelly C Lu
Journal:  Lab Invest       Date:  2008-08-11       Impact factor: 5.662

3.  N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis.

Authors:  January N Baumgardner; Kartik Shankar; Leah Hennings; Emanuele Albano; Thomas M Badger; Martin J J Ronis
Journal:  J Nutr       Date:  2008-10       Impact factor: 4.798

Review 4.  Pathophysiological basis for antioxidant therapy in chronic liver disease.

Authors:  Jesús Medina; Ricardo Moreno-Otero
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Protective effect of Salvia miltiorrhiza and Carthamus tinctorius extract against lipopolysaccharide-induced liver injury.

Authors:  Li-Na Gao; Kuo Yan; Yuan-Lu Cui; Guan-Wei Fan; Yue-Fei Wang
Journal:  World J Gastroenterol       Date:  2015-08-14       Impact factor: 5.742

6.  Methionine deficiency and hepatic injury in a dietary steatohepatitis model.

Authors:  Helieh S Oz; Theresa S Chen; Manuela Neuman
Journal:  Dig Dis Sci       Date:  2007-08-21       Impact factor: 3.199

7.  Folate deficiency disturbs hepatic methionine metabolism and promotes liver injury in the ethanol-fed micropig.

Authors:  Charles H Halsted; Jesus A Villanueva; Angela M Devlin; Onni Niemelä; Seppo Parkkila; Timothy A Garrow; Lynn M Wallock; Mark K Shigenaga; Stepan Melnyk; S Jill James
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-16       Impact factor: 11.205

Review 8.  S-adenosylmethionine in liver health, injury, and cancer.

Authors:  Shelly C Lu; José M Mato
Journal:  Physiol Rev       Date:  2012-10       Impact factor: 37.312

Review 9.  Advances in alcoholic liver disease.

Authors:  Zhenyuan Song; Swati Joshi-Barve; Shrish Barve; Craig J McClain
Journal:  Curr Gastroenterol Rep       Date:  2004-02

10.  Peroxisome proliferator-activated receptor and retinoic x receptor in alcoholic liver disease.

Authors:  Tommaso Mello; Simone Polvani; Andrea Galli
Journal:  PPAR Res       Date:  2009-09-14       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.